Reversing resistance to sunitinib: Findings may help patients with deadly kidney cancer

Researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma, a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.

Read the whole article on Science Daily

More from Science Daily